Denali Therapeutics Overview
- Year Founded
-
2015
- Status
-
Public
- Stock Symbol
-
DNLI
- Investments
-
3
- Share Price
-
$22.97
- (As of Friday Closing)
Denali Therapeutics General Information
Description
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Contact Information
Website
www.denalitherapeutics.comCorporate Office
- 161 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 161 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Denali Therapeutics Stock Performance
As of 13-Dec-2024, Denali Therapeutics’s stock price is $22.97. Its current market cap is $3.31B with 144M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $22.97 | $23.47 | $14.56 - $33.33 | $3.31B | 144M | 845K | -$2.75 |
Denali Therapeutics Financials Summary
As of 30-Sep-2024, Denali Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 3,323,112 | 1,910,349 | 2,732,969 | 4,472,868 |
| Revenue | 0 | 330,531 | 108,463 | 48,661 |
| EBITDA | (481,517) | (179,973) | (330,361) | (287,158) |
| Net Income | (427,493) | (145,224) | (325,991) | (290,581) |
| Total Assets | 1,454,013 | 1,153,917 | 1,460,242 | 1,404,162 |
| Total Debt | 52,517 | 52,241 | 60,350 | 64,007 |
Denali Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Denali Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Denali Therapeutics Comparisons
Industry
Financing
Details
Denali Therapeutics Competitors (62)
One of Denali Therapeutics’s 62 competitors is Alector, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alector | Formerly VC-backed | South San Francisco, CA | ||||
| CRISPR Therapeutics | Formerly VC-backed | Zug, Switzerland | ||||
| ZyVersa Therapeutics | Formerly VC-backed | Weston, FL | ||||
| Avidity Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA |
Denali Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Denali Therapeutics Patents
Denali Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240025915-A1 | Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile | Inactive | 25-Jul-2022 | ||
| US-20240317776-A1 | Solid forms of 4-(3,3-difluoro-2,2-dimethyl-propanoyl)-3,5-dihydro-2h-pyrido[3,4-f][1,4]oxazepine-9-carbonitrile | Pending | 25-Jul-2022 | ||
| AU-2023298154-A1 | Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells | Pending | 01-Jul-2022 | ||
| US-20230271978-A1 | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide | Active | 12-Jan-2022 | ||
| US-11999750-B2 | Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido [3,2-b][1,4]oxazepin-3-yl)-4h-1,2,4-triazole-3-carboxamide | Active | 12-Jan-2022 | C07D498/04 |
Denali Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Denali Therapeutics Investments & Acquisitions (3)
Denali Therapeutics’s most recent deal was a Merger/Acquisition with F-star Gamma for . The deal was made on 30-May-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| F-star Gamma | 30-May-2018 | Merger/Acquisition | Biotechnology | ||
| Incro Pharmaceuticals | 25-Aug-2016 | Merger/Acquisition | Biotechnology | ||
| F-star Gamma | 05-Jun-2016 | Secondary Transaction - Private | Biotechnology |
Denali Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
34.82 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,100
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Biotechnology
Subindustry
of 367
Rank
Percentile
Denali Therapeutics FAQs
-
When was Denali Therapeutics founded?
Denali Therapeutics was founded in 2015.
-
Where is Denali Therapeutics headquartered?
Denali Therapeutics is headquartered in South San Francisco, CA.
-
What industry is Denali Therapeutics in?
Denali Therapeutics’s primary industry is Biotechnology.
-
Is Denali Therapeutics a private or public company?
Denali Therapeutics is a Public company.
-
What is Denali Therapeutics’s stock symbol?
The ticker symbol for Denali Therapeutics is DNLI.
-
What is the current stock price of Denali Therapeutics?
As of 13-Dec-2024 the stock price of Denali Therapeutics is $22.97.
-
What is the current market cap of Denali Therapeutics?
The current market capitalization of Denali Therapeutics is $3.31B.
-
Who are Denali Therapeutics’s competitors?
Alector, CRISPR Therapeutics, ZyVersa Therapeutics, Avidity Biosciences, and Capricor Therapeutics are some of the 62 competitors of Denali Therapeutics.
-
What is Denali Therapeutics’s annual earnings per share (EPS)?
Denali Therapeutics’s EPS for 12 months was -$2.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
